


Form PTO-1449 (modified)



List of Patents and Publications for

INFORMATION DISCLOSURE STATEMENT

(Use several sheets if necessary)

Atty. Docket No.
11362.0039.NPUS01Serial No.
10/625,854Applicant
André Delacourte; Nicolas SergeantFiling Date:
July 23, 2003Group:
1645U.S. Patent Documents
See Page 1Foreign Patent Documents
See Page 1Other Art
See Pages 1-3

U.S. Patent Documents

Exam. Init.	Ref. Des.	Document Number	Date	Name	Class	Sub Class	Filing Date of App.
CYW	A1	Pub. No. US 2002/0094335	07/18/02	Chalifour et al.			
CYW	A2	4,666,829	05/19/87	Glenner et al.			
CYW	A3	5,876,948	03/02/99	Bruce A. Yankner			

Foreign Patent Documents

Exam. Init.	Ref. Des.	Document Number	Date	Country	Class	Sub Class	Translation Yes/No
CYW	B1	WO 03/000719	01/03/03	WIPO			
	B2	WO 02/096350	12/05/02	WIPO			
	B3	WO 00/72880	12/07/00	WIPO			
	B4	WO 98/44955	10/15/98	WIPO			
	B5	WO 96/28471	09/19/96	WIPO			
	B6	0 683 234	11/22/95	EPO			
	B7	WO 94/19692	09/01/94	WIPO			
CYW	B8	WO 92/03474	03/05/92	WIPO			

Other Art (Including Author, Title, Date Pertinent Pages, Etc.)

Exam. Init.	Ref. Des.	Citation
CYW	C1	Sergeant et al., "Truncated Beta-Amyloid Peptide Species in Pre-Clinical Alzheimer's Disease as New Targets for the Vaccination Approach," <i>Journal of Neurochemistry</i> , 85:1581-1591 (2003).
CYW	C2	Sigurdsson et al., "Immunization for Alzheimer's Disease," <i>Drug Development Research</i> , 56:135-142 (2002).
CYW	C3	Beka Solomon, "Immunological Concept in the Treatment of Alzheimer's Disease," <i>Drug Development Research</i> , 56:163-167 (2002).

EXAMINER:

DATE CONSIDERED:

12/10/06

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

INFORMATION DISCLOSURE STATEMENT — PTO-1449 (MODIFIED)

Form PTO-1449 (modified)		Atty. Docket No. 11362.0039.NPUS01	Serial No. 10/625,854
List of Patents and Publications for Applicant's INFORMATION DISCLOSURE STATEMENT (Use several sheets if necessary)		Applicant André Delacourte; Nicolas Sergeant	
		Filing Date: July 23, 2003	Group: 1645
U.S. Patent Documents See Page 1	Foreign Patent Documents See Page 1	Other Art See Pages 1-3	

Other Art (Including Author, Title, Date Pertinent Pages, Etc.)

Exam. Init.	Ref. Des.	Citation
Cyw	C4	Bruno P. Imbimbo, "β-Amyloid Immunization Approaches for Alzheimer's Disease," <i>Drug Development Research</i> , 56:150-162 (2002).
	C5	Tatsuya Inui, "Synthesis of Amyloid β-Peptides in Solution Employing Chloroform-Phenol Mixed Solvent for Facile Segment Condensation of Sparingly Soluble Protected Peptides," <i>Letters in Peptide Science</i> , 8:319-330 (2002).
	C6	Luigi Bergamaschini et al., "The Region 1-11 of Alzheimer Amyloid-β is Critical for Activation of Contact-Kinin System," <i>Neurobiology of Aging</i> , 22:63-69 (2001).
	C7	Dana Giulian et al., "The HHQK Domain of β-Amyloid Provides a Structural Basis for the Immunopathology of Alzheimer's Disease," <i>The Journal of Biological Chemistry</i> , 273(45):29719-29726 (1998).
	C8	V. Meske et al., "The Effects of β/A4-Amyloid and its Fragments on Calcium Homeostasis, Glial Fibrillary Acidic Protein and S100β Staining, Morphology and Survival of Cultured Hippocampal Astrocytes," <i>Neuroscience</i> , 85(4):1551-1660 (1998).
	C9	Michael Y. Aksenov et al., "Oxidative Modification of Glutamine Synthetase by Amyloid Beta Peptide," <i>Free Rad. Res.</i> , 27(3):267-281 (1997).
	C10	Rong Wang et al., "The Profile of Soluble Amyloid β Protein in Cultured Cell Media," <i>The Journal of Biological Chemistry</i> , 271(50):31894-31902 (1996).
	C11	Julia C. Hendrix et al., "A Convergent Synthesis of the Amyloid Protein of Alzheimer's Disease," <i>J. Am. Chem. Soc.</i> , 114:7930-7931 (1992).
	C12	Julia C. Hendrix et al., "Synthesis of a Protected Peptide Corresponding to Residues 1-25 of the β-Amyloid Protein of Alzheimer's Disease," <i>J. Org. Chem.</i> , 57:3421-3426 (1992).
	C13	Julia C. Hendrix et al., "Studies Related to a Convergent Fragment-Coupling Approach to Peptide Synthesis Using the Kaiser Oxime Resin," <i>J. Org. Chem.</i> , 57:3414-3420 (1992).
	C14	Julia C. Hendrix et al., "A Novel Solvent System for Solid-Phase Synthesis for Protected Peptides: The Disaggregation of Resin-Bound Antiparallel β-Sheet," <i>J. Org. Chem.</i> , 55:4517-4518 (1990).
	C15	Peter T. Lansbury, Jr. et al., "A Practical Method for the Preparation of Protected Peptide Fragments Using the Kaiser Oxime Resin," <i>Tetrahedron Letters</i> , 30(37):4915-4918 (1989).

EXAMINER: *Chang-hu Jung*DATE CONSIDERED: *1/27/06*

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

INFORMATION DISCLOSURE STATEMENT — PTO-1449 (MODIFIED)

Form PTO-1449 (modified)		Atty. Docket No. 11362.0039.NPUS01	Serial No. 10/625,854
List of Patents and Publications for Applicant's INFORMATION DISCLOSURE STATEMENT (Use several sheets if necessary)		Applicant André Delacourte; Nicolas Sergeant	
		Filing Date: July 23, 2003	Group: 1645
U.S. Patent Documents See Page 1	Foreign Patent Documents See Page 1	Other Art See Pages 1-3	

Other Art (Including Author, Title, Date Pertinent Pages, Etc.)

Exam. Init.	Ref. Des.	Citation
	C16	"Antibodies to Beta Amyloid Proteins", <i>Thalzheimer Research Forum</i> www.alzforum.org On-Line!, 3 June 2002 (retrieved on 2003-10-15).

EXAMINER: *Chang-fu J*DATE CONSIDERED: *1/27/06*

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

INFORMATION DISCLOSURE STATEMENT — PTO-1449 (MODIFIED)